Global Open Angle Glaucoma Market – Industry Trends and Forecast to 2030

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista Relatório de amostra grátis Relatório de amostra grátis Consulte antes Comprar Consulte antes  Comprar agora Comprar agora

Global Open Angle Glaucoma Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Reports
  • Jan 2023
  • Global
  • 350 Páginas
  • Número de tabelas: 220
  • Número de figuras: 60

Global Open Angle Glaucoma Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Chart Image USD 5.20 Million USD 7.12 Million 2022 2030
Diagram Período de previsão
2023 –2030
Diagram Tamanho do mercado (ano base )
USD 5.20 Million
Diagram Tamanho do mercado ( Ano de previsão)
USD 7.12 Million
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Aerie Pharmaceuticals
  • Abbvie
  • Bausch Health Companies
  • Merck & Co
  • Pfizer

Global Open Angle Glaucoma Market, By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, Others), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Open Angle Glaucoma Market

Open Angle Glaucoma Market Analysis and Size

As per the International Agency for the Prevention of Blindness: 2017, glaucoma is second top cause of blindness and main cause of irreversible blindness globally. The increasing elderly  population is one of the main factors for increasing incidence of glaucoma, which is anticipated to drive growth of the glaucoma therapeutics market in the near future. The increasing growth of open angle glaucoma market boosted by the rising cases of glaucoma and increase in R&D activities conducted by many pharmaceuticals’ companies

Data Bridge Market Research analyses a growth rate in the open angle glaucoma market in the forecast period 2023-2030. The expected CAGR of open angle glaucoma market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 5.2 million in 2022, and it would grow upto USD 7.12 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Open Angle Glaucoma Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, Others), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Aerie Pharmaceuticals, Inc. (U.S.), Abbvie, Inc (U.S.), Bausch Health Companies Inc (Canada), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Fera Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), EyePoint Pharmaceuticals,Inc (U.S.) Amorphex Therapeutics Holdings, Inc (U.S.), Kubota Vision Inc (U.S.), Alcon (Switzerland), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Novartis AG (U.S.), Carl Zeiss Meditec AG (Germany), Nidek Co Ltd (India), Accutome, Inc (U.S.),  AqueSys (U.S.), Iridex Corporation (U.S.)

Market Opportunities

  • Rising Incidence of Blindness Cases
  • Increasing Demand for Retail Pharmacies

Market Definition

The glaucoma is one of the top ocular disorders which results in the damage to the optic nerve. Glaucoma can cause vision loss and blindness. There are several drugs which are utilized for the diagnosis of this diseased condition. Some of them are alpha-adrenergic agonists, hyperosmotics, beta blockers, and carbonic anhydrase inhibitors. The most common types of glaucoma are primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG).

Open Angle Glaucoma Market Dynamics

Drivers

  • Increase in Elderly Population

The elderly population is anticipated to increase the demand of the disease globally during the forecast period. As per the records of the WHO, the elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. Thus, this increasing population will suffer from more ocular disorders especially glaucoma. This boost the market growth.

  • Growing Demand for Oral Drugs

Oral drugs is anticipated to boost the market growth. The segment is projected to increase the global market as most of the products are available in capsule form and tablet form and it is a very feasible route of administration especially for the elderly population.

Opportunities

  • Increasing Occurrence of Blindness Cases

As per the records of the International Agency for the Prevention of Blindness, it is projected that about 80 million people will suffer from glaucoma in 2020, a huge increase from 20 million witnessed in 2010. In addition to this, more than 8 million people were bilaterally blind because of glaucoma, which is anticipated to increase to over 14 million by 2022.

  • Growing Demand for Retail Pharmacies

The increase in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with suitable treatments could impede the growth of the global open angle glaucoma market during the forecast period.

  • High Cost of Treatment

The increased expenditure related with the treatment of open angle glaucoma medications hamper the market growth. Beta blockers, antagonists, prostaglandins, alpha adrenergic agonists, and carbonic anhydrase inhibitors will hamper the market growth by increasing costs.

This open angle glaucoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the open angle glaucoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2020, the two glaucoma treatments launched by Micro Labs USA were dorzolamide 2% and dorzolamide-timolol. Micro Labs USA plans to issue new ophthalmic products in stages of FDA evaluation and development to meet the increasing demand.
  • In 2019, Allergan Plc stated that the New Drug Application (NDA) for Bimatoprost Sustained-Release had been approved by the U.S. FDA. Bimatoprost SR would be the first-ever prolonged, reversible implant for the treatment of individuals with primary open-angle glaucoma or ophthalmic hypertension.

Global Open Angle Glaucoma Market Scope

The open angle glaucoma market is segmented on the basis of type, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Closed Angle Glaucoma (CAG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma
  • Others

Drug Class

  • Beta Blockers
  • Prostaglandins
  • Alpha Adrenergic Agonist
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Open Angle Glaucoma Market Regional Analysis/Insights

The open angle glaucoma market is analyzed and market size insights and trends are provided by type, drug class, distribution channel and end-user as referenced above.

The major countries covered in the open angle glaucoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a huge growth for open angle glaucoma market throughout the forecasted period because of the strong repayment rules and high incidence of patient’s pool.

North America dominates the market because of the high incidences of glaucoma, and the economic stability which outcomes to increased healthcare spending. Additionally, huge population suffering from diabetes and other eye diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Open Angle Glaucoma Market Share Analysis

The open angle glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to open angle glaucoma market

Key players operating in the open angle glaucoma market include:

  • Aerie Pharmaceuticals, Inc. (U.S.)
  • Abbvie, Inc (U.S.)
  • Bausch Health Companies Inc (Canada)
  • Merck & Co. Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Fera Pharmaceuticals (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • EyePoint Pharmaceuticals,Inc (U.S.)
  • Amorphex Therapeutics Holdings, Inc (U.S.)
  • Kubota Vision Inc (U.S.)
  • Alcon (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Bayer AG (Germany)
  • Novartis AG (U.S.)
  • Carl Zeiss Meditec AG (Germany)
  • Nidek Co Ltd (India)
  • Accutome,Inc (U.S.)
  • AqueSys (U.S.)
  • Iridex Corporation (U.S.)

SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

O mercado é segmentado com base em , By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, Others), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
O tamanho do Global Open Angle Glaucoma Market foi avaliado em USD 5.20 USD Million no ano de 2022.
O Global Open Angle Glaucoma Market está projetado para crescer a um CAGR de 4% durante o período de previsão de 2023 a 2030.
Os principais players do mercado incluem Aerie Pharmaceuticals, Abbvie, Bausch Health Companies, Merck & Co, Pfizer, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Kubota Vision, Alcon, Astellas Pharma, Bayer AG, Novartis AG, Carl Zeiss Meditec AG, Nidek Co Ltd, Accutome, AqueSys, Iridex Corporation.
O relatório de mercado cobre dados de U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Testimonial